Relationship between insulin-like growth factor-1 and cerebral small vessel disease and its mechanisms: advances in the field

Hao Du, Jian‐Chuan Xia, Lei Huang, Lan Zheng, Wenping Gu, Yi FangFrontiers in Aging Neuroscience 2023 · DOI

TL;DR

This review synthesizes emerging evidence that Insulin-like Growth Factor-1 (IGF-1) acts as a critical neuroprotective shield for the brain's delicate microvasculature. Low levels of IGF-1 are strongly linked to Cerebral Small Vessel Disease (cSVD), suggesting that this growth factor is essential for maintaining the blood-brain barrier and preventing the cognitive decline associated with aging and hypertension.

What Problem Does This Paper Address?

Cerebral Small Vessel Disease (cSVD) is a "silent" but devastating neurological condition. Unlike a major stroke that causes immediate, obvious paralysis, cSVD involves chronic damage to the brain's smallest arteries, capillaries, and venules. Over time, this leads to white matter lesions, microbleeds, and eventually, vascular cognitive impairment and dementia.

While we know that age and hypertension are major risk factors, the molecular mechanisms that protect (or fail to protect) these tiny vessels are not fully understood. This paper investigates the role of IGF-1—a hormone primarily known for childhood growth but which remains active throughout life—as a potential regulator of brain health. The authors tackle the question: Does a decline in IGF-1 leave the brain vulnerable to cSVD, and if so, how?

Methods

As a review article, this paper does not present a single new experiment. Instead, it synthesizes findings from dozens of recent clinical studies and animal models.

  • Clinical Synthesis: The authors compare data from human cohorts (e.g., the Framingham study) to correlate circulating IGF-1 levels with stroke incidence, cognitive scores (MoCA/MMSE), and MRI markers of cSVD.
  • Mechanistic Analysis: The paper reviews experimental work using IGF-1 deficient mouse models and "retina-as-a-window" studies to map out how IGF-1 interacts with the various cells of the brain.

Datasets

The paper draws upon several landmark clinical datasets and experimental models, including:

  • Human Cohorts: Data from various longitudinal studies involving elderly patients, diabetic populations, and stroke survivors (e.g., Johnsen et al., 2005; Saber et al., 2017).
  • Animal Models: Specifically, IGF-1 deficient mice and hypertensive rat models used to observe microvascular rarefaction (the loss of small blood vessels) and blood-brain barrier (BBB) leakage.
  • Imaging Data: MRI-based assessments of white matter hyperintensities (WMH) and cerebral microbleeds (CMBs).

Key Insights and Ideas

The authors highlight several "aha moments" regarding how IGF-1 protects the brain:

  • The Microglia "Switch": IGF-1 appears to regulate the polarization of microglia. In its presence, microglia favor the M2 phenotype (anti-inflammatory/repair), but when IGF-1 is low, they shift toward the M1 phenotype (pro-inflammatory), which exacerbates brain injury.
  • The Neurovascular Unit (NVU) Guardian: IGF-1 isn't just a "growth" factor; it's a structural stabilizer. It promotes the expression of tight junction proteins (like occludin and claudin-5), which are the "glue" that keeps the blood-brain barrier from leaking.
  • Hemodynamic Maladaptation: A fascinating insight is that IGF-1 deficiency impairs the brain's ability to auto-regulate blood flow. Without it, the brain cannot properly dilate small vessels in response to neural activity (neurovascular coupling), leading to chronic "mini-starvation" of brain tissue.
  • Retinal Mirroring: The paper discusses how changes in the retina often mirror cSVD in the brain, though it cautions that IGF-1 might not be a perfect universal biomarker for both.

Key Results

  • Clinical Correlation: Multiple studies show that patients in the lowest quartiles of serum IGF-1 have a significantly higher risk of ischemic stroke and poorer functional recovery.
  • Cognitive Impact: Low IGF-1 levels are positively correlated with hippocampal atrophy and lower scores on cognitive assessments like the Montreal Cognitive Assessment (MoCA).
  • Structural Protection: In animal models, IGF-1 administration reduced BBB permeability and decreased the volume of brain tissue lost after an induced stroke. Conversely, IGF-1 deficiency was shown to increase the frequency of cortical and subcortical microbleeds.

Limitations and Future Work

The authors acknowledge several hurdles before IGF-1 can be used as a clinical tool:

  1. Correlation vs. Causation: Most human data is observational. It remains unclear if low IGF-1 causes cSVD or is simply a marker of general frailty.
  2. The IGFBP Factor: IGF-1 doesn't travel alone; it's regulated by binding proteins (IGFBPs). The paper suggests that future research must look at the ratio of IGF-1 to its binding proteins, rather than just IGF-1 in isolation.
  3. Therapeutic Delivery: While IGF-1 therapy shows promise in mice, delivering it effectively to the human brain without causing systemic side effects (like hypoglycemia or unwanted cell growth) remains a major engineering challenge.

The paper concludes that while IGF-1 is a promising biomarker for cSVD severity, large-scale clinical trials are needed to determine if supplemental IGF-1 can actually halt the progression of vascular dementia.

Summary updated

Abstract

Insulin-like growth factor-1 (IGF-1) is an active polypeptide protein that closely resembles the structural sequence of insulin and is involved in a variety of metabolic processes in the body. Decreased IGF-1 circulation levels are associated with an increased risk of stroke and a poorer prognosis, but the relationship with cerebral small vessel disease (cSVD) is unclear. Some studies found that the level of IGF-1 in patients with cSVD was significantly reduced, but the clinical significance and underlying mechanisms are unknown. This article reviews the correlation between IGF-1 and cerebrovascular disease and explores the potential relationship and mechanism between IGF-1 and cSVD.
BibTeX
@inproceedings{du2023relationship,
  author = {Hao Du and Jian‐Chuan Xia and Lei Huang and Lan Zheng and Wenping Gu and Yi Fang},
  title = {{Relationship between insulin-like growth factor-1 and cerebral small vessel disease and its mechanisms: advances in the field}},
  booktitle = {Frontiers in Aging Neuroscience},
  year = {2023},
  doi = {10.3389/fnagi.2023.1190869},
}
Figure